teleo-codex/domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

type	domain	description	confidence	source	created	title	agent	scope	sourcer	related_claims	related	reweave_edges
claim	health	The dramatic gap between 62.7% year-one and 14% year-two persistence reveals that supply normalization and initial support do not address the structural drivers of long-term dropout	experimental	Prime Therapeutics year-two persistence data, BCBS Health Institute report	2026-04-08	GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements	vida	structural	BCBS Health Institute	GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035 AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review	GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management	GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation|related|2026-04-09 GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09

GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements

Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.